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doi:10.1016/j.ejvs.2010.01.030Abstract Background: Pharmaceutical stabilisation of the abdominal aortic aneurysm (AAA)
wall can delay surgery and improve outcome. Observational studies indicate statins can be
used to reduce AAA growth but mechanistic data are scarce. In this study, our aim was to
determine the pleiotropic effects of different statins on AAA wall composition.
Methods: We included 216 patients undergoing open AAA repair, of which 60 used simvastatin,
52 atorvastatin and 23 pravastatin. The AAA wall histology and protein expression
(IL 1b,2,4,5,6,8,10,12, interferon-gamma (IFNg), tumour necrosis factor (TNF)a,b, matrix me-
talloproteinase (MMP)2 and 9 activities, total MMP8,9 and cathepsin A and B levels) between
statin users and non-users were compared as also among the use of different statins.
Results: As far as histological inflammation goes, the AAA walls of statin users did not differ
from those not using them. After multivariate adjustment for risk factors, pravastatin use
was associated with tendencies of increased MMP8 (p Z 0.022), active MMP9 (p Z 0.040)
and higher cathepsin B (pZ 0.056) levels. The AAA walls of simvastatin and atorvastatin users
showed no differences in proteases or cytokines in multivariate analyses.
Conclusions: The use of statins was not associated with a decrease in protease levels or inflam-
mation. The trends of elevated protease levels associated with pravastatin use suggest pleio-
tropic differences among the various statins, supporting the need for further research to target
pharmaceutical AAA treatment.
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570 R. Hurks et al.Abdominal aortic aneurysm (AAA) formation is a degenera-
tive disease with a prevalence of 5.32e8.02%.1 Progressive
expansion of AAA eventually leads to rupture; it caused
6800 deaths in the UK in 2000.1e3 Preventive exclusion of
the AAA from circulation is associated with a mortality of
9.6%.4 As a consequence, pharmaceutical stabilisation of
the AAA wall is a promising target to postpone intervention
and thereby improve outcome.5 Various medications have
been suggested to inhibit AAA expansion of which some,
including roxithromycin6 and doxycycline,7 have been
tested in small randomised controlled trials. Observational
studies indicate AAA growth reduction by
hydroxymethylglutaryl-coenzyme A reductase inhibitors
(statins),8,9 but mechanistic data are scarce. In rodents,
atorvastatin and simvastatin are shown to suppress AAA
formation when compared to vehicle, independent of their
lipid-lowering effects.10e12 Moreover, statins are described
to have pleiotropic effects on the arterial wall, mainly
showing up in atherosclerotic plaques.13
In AAA pathophysiology, matrix metalloproteinases
(MMPs) are key molecules for aortic wall degradation;
MMP 9 especially has been studied extensively.14e16
Previous relatively small studies suggested that statin
use attenuates MMP activity, leading to a decreased AAA
growth rate.17,18 We aimed to confirm these findings and
add both cytokine data and histology, while correcting
for confounders to obtain more information on possible
mechanisms. Besides this, other studies suggest dissimilar
effects different types of statins have on serum lipid
levels and atherosclerotic plaque composition.19,20
Therefore, our aim also was to address possible differ-
ences between commonly prescribed statins on AAA wall
composition, including proteases, cytokines and histology
in a large patient cohort.
Methods
Patients and materials
A total of 216 consecutive patients from two centres
scheduled for operative open AAA repair were included in
the Aneurysm-express cohort study. The indication for
surgery was based on international standards.21 The ethical
review boards of the participating hospitals approved the
study and all patients signed a written informed consent.
Baseline characteristics of the patients who participated in
the Aneurysm-express study included medical history and
medication use. These data were extracted from clinical
patient records and a questionnaire based on the Rose
cardiovascular survey was filled in by the patients.22 In
cases of doubt or inconsistencies, the patients’ general
practitioner or pharmacist was contacted for further
details. The AAA diameter and morphology were assessed
via computed tomographic angiography or magnetic reso-
nance angiography. For all patients, protein was isolated
from the AAA wall and used for measuring cytokine and
protein levels. Blood samples were available for 100
patients and histology for 129. Total cholesterol, triglyc-
erides, high density lipoprotein cholesterol (HDL), low
density lipoprotein cholesterol (LDL) and high-sensitivity C-
reactive protein (hsCRP) were determined before surgery.Tissue processing
During surgery a part of the ventral AAA wall was harvested
at the site of maximum diameter, segmented and immedi-
ately processed. One segment was fixed using 4% formal-
dehyde, decalcified using ethylenediaminetetraacetic acid
(EDTA) and paraffin-embedded for histological stainings.
Adjacent segments were snap-frozen using liquid nitrogen
and stored at 80 C. The following stainings were per-
formed for AAA wall analysis: haematoxylin and eosin
(overview), elastica-Van Giesson (elastin), picrosirius red
(collagen), alpha smooth muscle actin (smooth muscle cells
(SMCs)), CD68 (macrophages), CD3 (T-lymphocytes), CD20
(B-lymphocytes) and CD138 (plasma cells). All stained
sections were scored semi-quantitatively on a two-value
scale (no to minor vs. moderate to heavy staining). Extra-
cellular matrix components (elastin, collagen) and cells
(SMCs, macrophages, T-lymphocytes, B-lymphocytes and
plasma cells) were scored for the total vessel wall.
Adjacent segments were used for protein isolation.
Samples were crushed in liquid nitrogen and afterwards
partly dissolved in 1.5 ml 40 mmol TrisHCl (Roche) and
centrifuged at max rpm and stored at 80 C. Another
segment was isolated using Tripure Isolation Reagent
(Boehringer Mannheim) according to the manufacturer’s
protocol. Protein concentrations were measured via the
BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
USA). Total amounts of MMP 8, 9, cathepsin A and B were
determined using the Bio-Plex system employing Lumi-
nex multianalyte profiling technology, as described and
performed previously.23,24 MMP activities were measured
using the Amersham matrix metalloproteinase 2 and 9
biotrak activity assay system (GE Healthcare UK
limited).
Levels of interleukin (IL) 1b, 2, 4, 5, 6, 8, 10, 12p70,
interferon (IFN) g and tumour necrosis factor (TNF) a and
b were quantified in the aneurysmal wall by fluorescent
bead immunoassay (Bendermed Systems).Statistical analyses
Demographic and clinical characteristics with discrete
variables were summarised as frequencies and percent-
ages and normal distributed continuous variables as
means and their standard deviation; non-normally
distributed continuous variables were presented as
median and interquartile range. Chi-square and Manne
Whitney tests were used for comparing discrete and
continuous variables, respectively between groups.
Multiple groups were compared using the KruskaleWallis
test. The association between statin groups and AAA-wall
characteristics was adjusted for cardiovascular risk
factors and baseline parameters showing an association
(p < 0.200) with statin use in the multivariate logistic
regression model. For this purpose, continuous variables
were dichotomised at the median. Dependent variable
was the measured protease, cytokine or histological
parameter. For each variable three models were run: one
with statin use included in the independent variables,
a second with the different statins and a third with statins
categorised according to their pharmacokinetic profile.
Different Statins and AAA Wall Biology 571The reported multivariate p represents the p-value of the
independent variable in the model. To correct for the five
simultaneous comparisons in the three models, we
applied Bonferroni’s method resulting in probability
values of <0.01 to be considered statistically significant.
All analyses were performed using statistical package of
the social sciences version 15 (SPSS Inc.).Results
The AAA diameter and morphology did not differ between
users and non-users of statins. Patients receiving statin
therapy exhibited a higher prevalence of cardiovascular
co-morbidities and risk factors as expected (Table 1).
Nearly all patients used their statins at least 1 month prior
to surgery. Blood was available from 100 patients,
included at the later period of the Aneurysm-express.
Serum levels of total cholesterol (p Z 0.001), LDL
(p Z 0.002) and HDL (p Z 0.038) were significantly lower
in statin-treated patients, while triglycerides and C-
reactive protein (CRP) were similar in groups (Table 1). No
differences were found between groups using of
angiotensin-converting enzyme (ACE)-inhibitors or angio-
tensin II receptor blockers.
The AAA walls of statin-treated patients had trends for
higher concentrations of active MMP2 (p Z 0.042) and
lower amounts of cathepsin A (p Z 0.041) compared with
patients not using statins; these tendencies did not sustain
after multivariate adjustment for cardiovascular risk
factors (Table 2). The analyses of effects of the different
statins compared with no statin use are summarised in
Table 2. Simvastatin use was associated with lower
cathepsin A levels in univariate (p Z 0.010) but not in
multivariate analysis. AAA patients using pravastatin had
tendencies for higher levels of active MMP2 (p Z 0.038),
higher active MMP9 (p Z 0.040) and higher MMP8
(p Z 0.068) compared with patients not using statins.
Multivariate adjustment for differences in risk factors
between patient groups revealed pravastatin use to be
associated with a trend for higher MMP8 (pZ 0.022), higher
active MMP9 (p Z 0.040) and higher cathepsin B levels
(p Z 0.056).
Patients using atorvastatin showed no difference in
protease levels compared to non-users in the multivariate
analyses. Statin treatment did not result in differences in
the tested cytokines compared with patients not using
statins, which holds true for all statins and individual sta-
tins as well.
Histology was available for 129 patients (Table 3). We
found no differences in histology between statin and non-
statin users for structural components (elastin, collagen
and SMC presence). No differences were observed for CD20-
B-lymphocytes, CD138-plasmacells or CD68-macrophages.
CD3-T-lymphocytes revealed a higher tendency in the pra-
vastatin group in uni- and multivariate analysis (p Z 0.037
and p Z 0.045, respectively).
To further assess the differences among statins, we
grouped them based on their pharmacokinetic profiles25:
lipophilic (simvastatin and atorvastatin) versus hydro-
philic (pravastatin). When these groups were compared
for proteases (Table 4), MMP8 and cathepsin B showeda higher tendency in the hydrophilic group (p Z 0.019
and p Z 0.027). Multivariate adjustment for cardiovas-
cular risk factors showed higher trends in MMP8, active
MMP9 and cathepsin B in the hydrophilic pravastatin
(p Z 0.023, p Z 0.040 and p Z 0.055, respectively).
Histological comparison revealed a higher tendency of T-
lymphocytes in AAA walls from pravastatin-treated
patients compared with the combined hydrophilic sta-
tins in uni- and multivariate analysis (p Z 0.034 and
p Z 0.043, respectively).Discussion
We found in our large cohort of patients no independent
significant effects of statins as a group on proteases,
cytokines and histology in harvested AAA walls. Analysing
individual statins after correction for differences in base-
line characteristics and cardiovascular risk factors, we
found that simvastatin and pravastatin did not stand out in
any of the analyses. Surprisingly, pravastatin use was
associated with higher trends for MMP8, MMP9 and
cathepsin B levels.
As we previously have shown, simvastatin, pravastatin or
atorvastatin use was not associated with altered MMP2 or 9
activities in atherosclerotic plaques.20 In vitro, animal
macrophages and SMCs produce less active MMP2 and 9 in
response to fluvastatin and simvastatin.26,27 In AAA walls,
however, lymphocytes outnumber macrophages by far and
SMC content is strongly diminished due to apoptosis,28,29
indicating that findings in atherosclerotic plaques do not
necessarily equal those in AAA walls. In addition, in a large
observational study, our group showed that statin use is
independently associated with attenuation of AAA growth
rate.8 This finding was also observed in another AAA
cohort.9 The mechanisms responsible for the decreased
growth remain to be clarified. Since MMP concentrations
are elevated in AAA tissue compared to normal aortic
tissue, many researchers focus on the role of MMPs in AAA
pathogenesis.16 Relatively small studies have been con-
ducted to determine the effects of statins on MMP activity
in AAA walls. Compared to patients without statins, statin
use is associated with less active MMP3 and 9 and lower
cathepsin H and L concentrations. In addition, no differ-
ences were found in total MMP1, 2, 8, 13.17,18 A small
randomised trial showed less active and total MMP9 in
patients treated with simvastatin as compared with those
given a placebo.30 Encouraged by these data, we wanted to
confirm these results and demonstrate a relation with
inflammatory markers in the AAA walls of patients enrolled
in our biobank study. We found trends for increased active
MMP2 and lower cathepsin A levels in statin-treated
patients in our cohort, which seemed due to pravastatin
use (p Z 0.038). However, in multivariate analyses, these
trends disappeared. Higher tendencies of total MMP8 and
active MMP9 levels were independently associated with
pravastatin use as compared to no statin use. When the
different pharmacokinetic properties of the statins were
taken into account, we noted the same pattern. Use of the
hydrophilic pravastatin was associated with increased
trends of MMP8 and cathepsin B compared to lipophilic
simvastatin and atorvastatin use. After multivariate
Table 1 Baseline characteristics.
No statin All statins P Simvastatin Ato astatin Pravastatin P
N 81 135 60 52 23
Age (years) 71.7  6.6 68.5  7.2 0.001 68.4  6.8 68.  7.4 69.8  7.7 0.625
Male (%) 59(73) 113(84) 0.143 51(85) 41( ) 21(91) 0.373
Diameter (mm) 62.3  10.6 64.0  13.9 0.682 64.6  14.0 61.  13.3 67.2  15.0 0.225
Fusiform morphology (%) 68(84) 113(84) 0.801 49(82) 45( ) 19(83) 0.777
Current smoker (%) 34(42) 63(47) 0.722 30(50) 22( ) 11(48) 0.495
Treatment for hypertension (%) 49(60) 106(79) 0.013 51(85) 41( ) 14(61) 0.058
Diabetes Mellitus (%) 5(6) 23(17) 0.025 10(17) 8(1 5(22) 0.794
COPD (%) 17(21) 20(15) 0.227 8(13) 7(1 5(22) 0.593
BMI (kg/m2) 24.9 [23.2e27.8] 26.1 [23.9e28.7] 0.214 25.5 [24.1e28.0] 26. [23.1e29.0] 27.0 [23.2e30.3] 0.456
GFR (ml/min/1.73 m2) 70.2 [61.1e78.7] 69.6 [54.4e92.7] 0.981 67.9 [54.9e86.8] 76. [54.9e95.6] 66.5 [51.8e93.2] 0.388
History of myocardial
infarction (%)
9(11) 56(41) <0.001 21(35) 23( ) 12(52) 0.357
ACE-inhibitor use (%) 22(27) 43(32) 0.502 19(32) 19( ) 5(22) 0.550
Angiotensin II receptor blockers(%) 13(16) 33(24) 0.157 15(25) 13( ) 5(22) 0.547
Peripheral artery disease(%) 12(15) 26(19) 0.429 16(27) 7(1 3(13) 0.151
Other aneurysm
reported (%)
9(11) 17(13) 0.795 4(7) 9(1 4(17) 0.181
N 33 67 24 32 11
Total cholesterol (mmol/l) 5.41 [4.31e6.47] 4.26 [3.48e4.86] 0.001 4.40 [4.04e5.12] 3.8 [2.86e4.68] 4.57 [4.13e5.07] 0.062
Triglycerides (mmol/l) 1.38 [1.00e2.13] 1.36 [0.96e2.12] 0.648 1.61 [1.24e2.21] 1.2 [0.79e2.07] 1.20 [0.96e2.04] 0.229
HDL (mmol/l) 1.04 [0.85e1.40] 0.90 [0.74e1.09] 0.039 0.91 [0.77e1.08] 0.8 [0.69e1.13] 0.94 [0.78e1.23] 0.749
LDL (mmol/l) 3.46 [2.49e4.35] 2.58 [2.00e3.04] 0.002 2.70 [2.27e3.18] 2.2 [1.50e3.01] 2.63 [2.43e3.12] 0.160
hsCRP (mg/l) 4.4 [2.4e10.2] 4.1 [1.7e13.3] 0.839 4.0 [2.2e9.9] 4.0 1.2e16.6] 4.2 [2.8e15.9] 0.920
Abbreviations: COPD, chronic obstructive pulmonary disease; BMI, body mass index; GFR, glomerular filtration rate; ACE, angiotensin onverting enzyme; HDL, high density lipoprotein;
LDL, low density lipoprotein; hsCRP, high-sensitivity C-reactive protein. Values are mean  standard deviation, median with [interqu rtile range] or in frequencies with (percentages).
P-values represent all statins combined versus no statin and differences among statin groups.
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Table 2 Protease and cytokine levels.
No statin All statins P a Simvastatin P a Atorvastatin P a Pravastatin P a
N 81 135 60 52 23
Active MMP 2 0.19
[0.03e0.33]
0.24
[0.11e0.47]
0.536 0.23
[0.12e0.45]
0.526 0.23
[0.08e0.40]
0.838 0.36
[0.11e0.66]
0.452
Total MMP 8 1919
[650e3826]
1819
[615e4324]
0.452 1658
[604e4138]
0.506 1406
[408e3839]
0.794 3515
[1593e9822]
0.022
Active MMP 9 0.16
[0e0.52]
0.31
[0.04e1.00]
0.404 0.25
[0.05e0.93]
0.298 0.24
[0.04e0.98]
0.403 0.40
[0.07e1.74]
0.040
Total MMP 9 8218
[2999e18680]
10668
[3703e24783]
0.931 10340
[5228e22080]
0.974 8522
[3145e29881]
0.686 14121
[7040e60525]
0.308
Total Cathepsin
A
2950
[1270e5837]
1725
[149e4820]
0.478 1192
[164e3766]
0.357 1951
[93e5312]
0.502 4546
[210e7050]
0.848
Total Cathepsin
B
13329
[9246e21219]
13359
[8352e20001]
0.558 11815
[8352e18372]
0.583 13359
[6525e19948]
0.568 16611
[12462e25783]
0.056
IL1b 0.01
[0e0.58]
0.03
[0e0.41]
0.630 0.11
[0e0.47]
0.438 0
[0e0.30]
0.703 0
[0e0.76]
0.747
IL2 1.87
[0.81e5.43]
2.48
[0.97e4.06]
0.126 2.51
[1.22e3.59]
0.117 2.52
[1.02e4.79]
0.100 1.37
[0.07e2.74]
0.789
IL4 0.04
[0e1.13]
0
[0e0.69]
0.884 0
[0e0.86]
0.370 0
[0e0.77]
0.792 0
[0e0.17]
0.603
IL5 0.86
[0.16e2.41]
0.64
[0e1.98]
0.600 0.55
[0e1.87]
0.721 0.89
[0.11e3.03]
0.350 0.42
[0e1.93]
0.611
IL6 1.91
[0.13e8.35]
0.82
[0.15e2.96]
0.800 0.67
[0.13e2.12]
0.982 1.34
[0.21e5.40]
0.749 1.20
[0.14e12.99]
0.704
IL8 26.32
[10.82e59.12]
26.15
[11.52e54.61]
0.664 24.30
[11.01e50.26]
0.657 28.96
[7.76e65.27]
0.934 23.79
[13.92e54.14]
0.288
IL10 0.27
[0e1.36]
0.46
[0e1.05]
0.393 0.47
[0e1.03]
0.453 0.58
[0e1.13]
0.148 0.09
[0e1.13]
0.305
IL12 0.46
[0.06e1.66]
0.29
[0e1.13]
0.629 0.31
[0e1.02]
0.984 0.32
[0e1.32]
0.719 0.12
[0e0.92]
0.244
TNFa 0.43
[0e1.17]
0.40
[0e0.79]
0.463 0.41
[0e0.78]
0.597 0.40
[0e0.91]
0.690 0.26
[0.01e0.95]
0.284
TNFb 0.35
[0e3.70]
0.33
[0e2.32]
0.737 0.78
[0e2.08]
0.560 0.28
[0e3.10]
0.768 0.15
[0e2.86]
0.723
IFNg 0.73
[0.28e2.11]
0.71
[0.14e1.73]
0.873 0.69
[0.34e1.76]
0.655 0.92
[0.16e2.13]
0.555 0.25
[0.02e1.36]
0.163
MMP is matrix metalloproteinase, IL is interleukin, TNF is tumor necrosis factor and IFN is interferon. Total proteases are in arbitrary units, protease activities are in ng/ml/12 ug protein
and cytokines are in ng/ml. Values are median with [interquartile range]. P-values originate from two multivariate models: one with statin use as a group and a second with different
statins separately.
a Adjusted for: age, gender, hypertension, diabetes, history of myocardial infarction.
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574 R. Hurks et al.adjustment the trends in MMP8 sustained, cathepsin B
diminished (likely underpowered) and active MMP9 was
added. The hydrophilic molecular structure of pravastatin
prevents widespread tissue distribution, and reduces the
potential for uptake by peripheral cells including those in
the arterial and AAA wall components. In addition, pra-
vastatin has higher unbound circulating levels and accord-
ing bioavailability when compared to simvastatin and
atorvastatin.25 These pravastatin-specific properties might
contribute to the associations with elevated proteases in
this study in contrast with the lack of established associa-
tions with wall components and the lipophilic statins, both
of which have not been reported before.
We evaluated the cytokine levels in the aneurysmal
walls in all groups to exclude the possibility of confounding
due to more inflammation-rich aneurysms in the pravas-
tatin group. Analyses showed no difference in inflamma-
tory status between the groups, which was also confirmed
by similar serum hsCRP levels in all groups. Histology too
showed no differences in structural components and
nearly all inflammatory cells. T-lymphocytes had a higher
trend in the pravastatin-treated group, also after multi-
variate adjustment. However, this difference was based
on a lower number of patients and needs to be interpreted
carefully.
This study has some limitations. The use of statins for
indications other than the AAA probably resulted in
differences in cardiovascular risk profile and patient
characteristics between statin users and non-users.
However, none of these differences was associated with
the levels of proteases, neither in univariate nor in
multivariate analyses. The number of patients was too low
to assess doseeresponse phenomena. Start date of statin
use was not known for all patients, but was not likely to
have influenced our results, since statins were reported to
influence the vessel wall after only 3 weeks of treat-
ment,30 and in our study nearly all patients had used
statins at least 1 month prior to surgery. Finally, this is an
observational cohort study evaluating possible effects of
statins on histological characteristics and proteases in AAA
walls, and should therefore be considered as hypothesis-
generating. In order to generate further evidence for
effects of statins on AAA wall components, confirmative
randomised trials are required.
The higher tendencies of MMP8 and 9 associated with
pravastatin use indicate possible pleiotropic differences
among the different statins. The effects of statins on
alterations in AAA pathogenesis and the slowing down of
AAA progression may be based on other proteases and
inflammation markers than those measured in our study.
We could not confirm results from previous findings of
statins on AAA wall biology. The mechanisms of actions
of statins on various AAA wall components, and
biomarkers of those, remain to be unrevealed.
Prescribing a low-dose statin for stabilising a patient’s
AAA is still not warranted when solely based on changes
in AAA wall composition. Statin use should be advocated
in line with clinical guidelines in this population with
many cardiovascular risk factors and co-morbidities.
Prospective clinical trials are needed to determine the
exact effects of statins on AAA progression and ulti-
mately rupture.
Table 4 Associations among statin groups based on their pharmacokinetic properties.
Lipophilic statin P a Hydrophilic statin P a
N 112 23
Active MMP 2 0.23 [0.11e0.42] 0.628 0.36 [0.11e0.66] 0.452
Total MMP 8 1605 [580e4001] 0.848 3515 [1593e9822] 0.023
Active MMP 9 0.24 [0.04e0.95] 0.721 0.40 [0.07e1.74] 0.040
Total MMP 9 9837 [3501e23291] 0.816 14121 [7040e60525] 0.310
Total Cathepsin A 1482 [144e4089] 0.365 4546 [210e7050] 0.846
Total Cathepsin B 13078 [7819e18584] 0.959 16611 [12462e25783] 0.055
N 70 12
Elastin (%) 16(14) 0.477 5(42) 0.352
Collagen (%) 40(36) 0.516 6(50) 0.805
Smooth muscle
cells (%)
31(28) 0.943 6(50) 0.801
Macrophages (%) 14(13) 0.234 3(25) 0.808
T-lymphocytes (%) 24(21) 0.994 8(67) 0.043
B-lymphocytes (%) 32(29) 0.766 4(33) 0.592
Plasmacells (%) 26(23) 0.904 3(25) 0.430
Lipophilic statins are simvastatin and atorvastatin, hydrophilic statin is pravastatin. MMP is matrix metalloproteinase. Total proteases
are in arbitrary units and protease activities are in ng/ml/12 ug protein. Values are median with [interquartile range]. Numbers are
absolute and represent moderate to high staining with (percentages) of total.
a Adjusted for: age, gender, hypertension, diabetes, history of myocardial infarction.
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